Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.41 |
| ▸ | CTSL | P07711 | 5/20 | 0.38 |
| ▸ | CTSB | P07858 | 5/20 | 0.38 |
| ▸ | CTSH | P09668 | 2/20 | 0.38 |
| ▸ | GRN | P28799 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12220087 | 1.00 | CTSK (0.41) | CTSKCTSLCTSBCTSHGRN | |
| SCHEMBL13909105 | 1.00 | CTSK (0.41) | CTSKCTSLCTSBCTSHGRN | |
| SCHEMBL12727416 | 0.98 | CTSK (0.43) | CTSKCTSLCTSBCTSHGRN | |
| SCHEMBL10442075 | 0.98 | CTSK (0.43) | CTSKCTSLCTSBCTSHGRN | |
| SCHEMBL8310083 | 0.98 | CTSK (0.43) | CTSKCTSLCTSBCTSHGRN | |
| SCHEMBL12220084 | 0.96 | CTSK (0.37) | CTSKCTSLCTSBCTSHGRN | |
| SCHEMBL14898377 | 0.96 | CTSK (0.37) | CTSKCTSLCTSBCTSHGRN | |
| SCHEMBL13127846 | 0.96 | CTSK (0.37) | CTSKCTSLCTSBCTSHGRN | |
| SCHEMBL24233279 | 0.92 | GRN (0.36) | CTSKCTSLCTSBCTSHGRN | |
| SCHEMBL8291760 | 0.92 | GRN (0.36) | CTSKCTSLCTSBCTSHGRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-11072634-B2 | Inhibitors of transglutaminases | ZEDIRA GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| US-20210147478-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | ZEDIRA GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| WO-2020131282-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS CORP. (MC) | 2020-06-25 | — | — | WO | disclosed |
| WO-2019201432-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019202052-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | WO | disclosed |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| WO-2018122419-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2018-07-05 | — | — | WO | disclosed |
| EP-3342779-A1 | INHIBITORS OF TRANSGLUTAMINASES | Zedira GmbH (DE) | 2018-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147478-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | TFPI, F11, F13B | CTSK 457/4885CTSL 238/4885CTSB 343/4885 |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | CTSK 410/4885CTSL 828/4885CTSB 289/4885 |
| US-11072634-B2 | Inhibitors of transglutaminases | TGM2, TGM3, TGM1 | CTSK 410/4885CTSL 828/4885CTSB 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.